Flexion Therapeutics (NASDAQ:FLXN) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Wednesday, BidAskClub reports.
A number of other analysts have also issued reports on the company. Needham & Company LLC cut their target price on Flexion Therapeutics from $30.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Northland Securities initiated coverage on Flexion Therapeutics in a research report on Thursday, August 6th. They issued a “buy” rating and a $35.00 target price on the stock. Zacks Investment Research lowered Flexion Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 4th. Royal Bank of Canada cut their target price on Flexion Therapeutics from $20.00 to $18.00 and set an “outperform” rating on the stock in a research report on Friday, May 8th. Finally, ValuEngine raised Flexion Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $21.57.
FLXN stock opened at $11.51 on Wednesday. The firm has a market cap of $572.35 million, a PE ratio of -3.21 and a beta of 2.07. The company has a debt-to-equity ratio of 13.18, a quick ratio of 6.08 and a current ratio of 6.60. The firm’s 50 day moving average price is $12.65 and its 200-day moving average price is $11.73. Flexion Therapeutics has a one year low of $5.01 and a one year high of $22.98.
Veteran trader Bryan Bottarelli has distilled all of the tricks, tips and strategies he learned in the live trading pit of the Chicago Board Options Exchange…And revealed them all in this easy-to-read e-book.
Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings results on Wednesday, August 5th. The specialty pharmaceutical company reported ($0.76) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.06). Flexion Therapeutics had a negative net margin of 174.25% and a negative return on equity of 592.50%. Equities research analysts predict that Flexion Therapeutics will post -2.72 EPS for the current fiscal year.
Several large investors have recently made changes to their positions in FLXN. Point72 Hong Kong Ltd purchased a new stake in Flexion Therapeutics during the 2nd quarter worth $31,000. Private Advisor Group LLC purchased a new stake in Flexion Therapeutics during the 2nd quarter worth $40,000. Paloma Partners Management Co purchased a new stake in Flexion Therapeutics during the 1st quarter worth $92,000. AQR Capital Management LLC purchased a new stake in Flexion Therapeutics during the 1st quarter worth $101,000. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Flexion Therapeutics during the 1st quarter worth $113,000. 82.19% of the stock is owned by institutional investors and hedge funds.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.
Read More: How is Preferred Stock Different from Common Stock?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
15 REITS Analysts Can’t Stop Recommending
There are more than 200 publicly-traded real-estate investment trusts (REITs) that you can buy through your brokerage account. Given the sheer number of REITs, it can be hard to identify which real-estate stocks are going to outperform the market.
Fortunately, Wall Street’s brightest minds have already done this for us. Every year, analyst issue approximately 4,000 distinct recommendations for REITs. Analysts don’t always get their “buy” ratings right, but it’s worth taking a hard look when several analysts from different brokerages and research firm are giving “strong buy” and “buy” ratings to the same REIT.
This slide show lists the 15 REITs that have the highest average analyst recommendations from Wall Street’s equities research analysts over the last 12 months.
